Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Investor Presentation (July 2012)
19 slides from Mayne Pharma's investor presentation, Jul 5, 2012
Slide 1: Mayne Pharma Group Limited Business update
For personal use only Mayne Pharma Group Limited Business update 5 July 2012
Slide 2: Today's presenters
Today’s presenters For personal use only Scott Richards Mark Cansdale CEO CFO Managing Director Company Secretary Appointed Feb 2012 Appointed Dec 2010 24 years global pharma industry experience 20+ years experience Prior experience: Prior experience: – President, European Operations and
Slide 3: Agenda
Agenda For personal use only Section Page 1 Overview of Mayne Pharma 3 2 Business segments 6 3 Growth drivers 10 4 Financial summary 15 5 FY12 guidance and outlook 16 www.maynepharma.com 2
Slide 4: Overview of Mayne Pharma
1 Overview of Mayne Pharma For personal use only Executive summary Sales revenue by business (excl. R&D income) Mayne Pharma Group Limited (“Mayne”) is an ASX-listed specialty FY 2011 pharmaceutical company – has its origins as the drug delivery technology arm of FH Faulding & Co 22% MP Global I
Slide 5: Evolution of Mayne Pharma
1 Evolution of Mayne Pharma For personal use only 1845 1970s • Development of enteric coated erythromycin (Eryc®) • FDA approval and first US sales of Eryc® by Warner Lambert (Chilcott) 1980s • Salisbury site acquired in 1983 by F H Faulding & Co Limited FH Faulding & Co • Development of: delayed re
Slide 6: Mayne's organisational chart
1 Mayne’s organisational chart Expanded/enhanced management capabilities to drive business development activities For personal use only Scott Richards Mark Cansdale CEO CFO Managing Director Company Secretary Vince Caretti Peter Truelove Stuart Mudge Stefan Lukas Christelle Simpson Operations Direct
Slide 7: Business segments
2 Business segments For personal use only Develop and manufacture proprietary and generic products using oral drug delivery technologies: For out-licence For domestic sale Research and Contract manufacture MP Global Mayne Pharma Australia development FY11 Sales Revenue A$27m A$9m na A$11m Key • Dory
Slide 8: MP Global (out licensing) and Mayne Pharma Australia
MP Global (out licensing) and 2 Mayne Pharma Australia For personal use only MP Global Mayne Pharma Australia • Out-licensing of proprietary pharmaceuticals • Manufacture, distribution and marketing of globally proprietary pharmaceuticals in Australia • Long standing customer relationships with lead
Slide 9: Research & Development
2 Research & Development For personal use only R&D review R&D capability 90 day R&D review examined the top 400 US molecules • Three of the most successful products developed by sales by MPG were responsible for ~$2.5 billion3 in in- Primary selection criteria: market US sales over the last 5 ye
Slide 10: Contract development and manufacturing
2 Contract development and manufacturing For personal use only Mayne provides a range of services to third parties: Overview of facilities The Company focuses on assisting partners in the areas of: Mayne’s 32 acre facility at Salisbury, South Australia has 12,000m2 of manufacturing space with TGA,
Slide 11: Strategic priorities
3 Strategic priorities Play to strengths while diversifying earnings base in complementary products, For personal use only technologies and market segments Leverage off MP • Re-establish global visibility of the Mayne Pharma brand brand globally • Targeted in-licensing of niche generic and specialty
Slide 12: Drug delivery systems
3 Drug delivery systems For personal use only Description of technologies Benefits Steady levels of drug concentrations over 12–24 Sustained release hours following a single dose Decreased dosing frequency and increased compliance Immediate release of a small portion of drug Reduced peak-to-trough r
Slide 13: SUBACAP overview
3 SUBACAP® overview For personal use only Overview of SUBACAP® Market potential Targeting the global itraconazole market Significantly improved formulation of itraconazole (anti- >US$500 million ex wholesale sales in 2011 and fungal product) based on SUBA® technology (improved stable1 bioavailab
Slide 14: SUBACAP—market update
3 SUBACAP®—market update For personal use only Europe • On 20 June 2012, following six months of consultation with Mayne Pharma, the UK Medicines and Healthcare Regulatory Agency (“MHRA”) reversed its previous decision on SUBACAP® and advised that: – the SUBACAP® Marketing Authorisation Application
Slide 15: Doryx patent—situation overview
3 Doryx® patent—situation overview For personal use only Doryx patent—situation overview Update Doryx® is a doxycycline formulation containing Doryx® appeal has been filed with the US enteric - coated delayed release pellets designed Court of Appeals for the Federal Circuit to minimise nausea wh
Slide 16: Group financial summary
4 Group financial summary For personal use only Summary P&L Summary balance sheet A$m, JunYE, reported FY11 HY12 A$m 30 Jun 11 31 Dec 11 Sales revenue1 47.0 26.8 Cash 5.8 6.1 EBITDA (underlying) 9.2 6.3 PP&E 21.5 22.2 Total Assets 53.7 55.4 EBITDA underlying margin % 19.6 23.5 Debt (2.3) Nil Adjustm
Slide 17: FY12 guidance
5 FY12 guidance For personal use only A$m, JunYE, reported* Expectation Sales revenue $51–53 million Sales revenue growth ~10% p.a. Underlying operating earnings (EBITDA) $10–12 million Cash (up $5.5 million from 31 December 2011) $11.6 million Debt Nil * Results are subject to completion of year-en
Slide 18: Outlook
5 Outlook For personal use only Milestone achieved SUBACAP® approvable in UK R Debt paid down R Milestones achieved Appointment of Adelaide–based CEO and Sales and Marketing director R Commencement of two new R&D projects R Renegotiated major contract customer for a further 3 years R Man
Slide 19: Disclaimer
Disclaimer For personal use only This presentation is the property of Mayne Pharma Group Limited (Mayne Pharma). This presentation is not and does not constitute an offer, invitation or recommendation to subscribe for, or purchase any security and neither this presentation nor anything contained in
Mayne Pharma Group — Investor Presentation (July 2012) on 6ix